Clinical trials: Migraine Prophylaxis
Migraine
MLD10 in the Prevention of Migraine in Adults
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm…
- Trial name
- NCT02322333
- Testing
- MLD10
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Pharmalyte Solutions LLC
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
- Trial name
- STRIVE (NCT02456740)
- Testing
- Erenumab
- Where
- 129 sites in United States, Austria and 11 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label phase.
- Trial name
- NCT00168428
- Testing
- Botulinum Toxin Type A
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 705 people
- Sponsor
- Allergan
Migraine Headache
Pilot Study of BOTOX for Migraine Headaches
The purposes of this study are to assess whether subjects treated with BOTOX will: 1. have a decrease in the frequency and intensity of migraine headaches 2. experience improvements in quality of life 3.
- Trial name
- NCT00850421
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- HealthPartners Institute
Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03777059
- Testing
- Atogepant
- Where
- 138 sites in United States
- Volunteers
- 910 people
- Sponsor
- Allergan
Migraine
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase (OLTP).
- Trial name
- NCT02630459
- Testing
- Erenumab
- Where
- 44 sites in Japan
- Volunteers
- 475 people
- Sponsor
- Amgen
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Chronic Migraine
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect preliminary clinical data related to the safety and clinical benefits of daily use of…
- Trial name
- NCT01667250
- Testing
- GammaCore Active Device
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- ElectroCore INC
Migraine Disorders
BOTOX® Prophylaxis in Patients With Chronic Migraine
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic…
- Trial name
- NCT01432379
- Testing
- botulinum toxin Type A
- Where
- 4 sites in Germany, Spain and 2 more
- Volunteers
- 1,168 people
- Sponsor
- Allergan
Migraine
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic…
- Trial name
- NCT03488563
- Testing
- B244, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Migraine
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
- Trial name
- NCT00812006
- Testing
- rizatriptan benzoate
- Volunteers
- 108 people
- Sponsor
- Organon and Co
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie
Chronic Migraine, Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
- Trial name
- JPN ATO OLE (NCT04437433)
- Testing
- Atogepant 60 mg
- Where
- 24 sites in Japan
- Volunteers
- 186 people
- Sponsor
- AbbVie
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Chronic Migraine
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Trial name
- NCT03855137
- Testing
- Atogepant 30 mg, Atogepant 60 mg
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 778 people
- Sponsor
- Allergan
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Randomized study of two digital therapeutics for the prevention of episodic migraine
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- ReMMi-D (NCT05853900)
- Testing
- ReMMi-D Digital Therapeutic
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- Click Therapeutics, Inc.